These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 29512720

  • 1. Alogliptin alleviates hepatic steatosis in a mouse model of nonalcoholic fatty liver disease by promoting CPT1a expression via Thr172 phosphorylation of AMPKα in the liver.
    Tobita H, Sato S, Yazaki T, Mishiro T, Ishimura N, Ishihara S, Kinoshita Y.
    Mol Med Rep; 2018 May; 17(5):6840-6846. PubMed ID: 29512720
    [Abstract] [Full Text] [Related]

  • 2. LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway.
    Chen XY, Cai CZ, Yu ML, Feng ZM, Zhang YW, Liu PH, Zeng H, Yu CH.
    World J Gastroenterol; 2019 Dec 07; 25(45):6607-6618. PubMed ID: 31832001
    [Abstract] [Full Text] [Related]

  • 3. Crocin ameliorates hepatic steatosis through activation of AMPK signaling in db/db mice.
    Luo L, Fang K, Dan X, Gu M.
    Lipids Health Dis; 2019 Jan 08; 18(1):11. PubMed ID: 30621686
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Mixture of five herbal extracts ameliorates pioglitazone-induced aggravation of hepatic steatosis via activating the adiponectin receptor 2/AMP-activated protein kinase signal pathway in diabetic KKAy mice.
    Wang H, Qin L, Wang D, Jiang Y, Wu X, Xu T, Liu T, Li L.
    J Tradit Chin Med; 2017 Oct 08; 37(5):588-598. PubMed ID: 32188218
    [Abstract] [Full Text] [Related]

  • 6. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
    Dusabimana T, Park EJ, Je J, Jeong K, Yun SP, Kim HJ, Kim H, Park SW.
    Int J Mol Sci; 2021 May 24; 22(11):. PubMed ID: 34073834
    [Abstract] [Full Text] [Related]

  • 7. Alisol A 24-Acetate Prevents Hepatic Steatosis and Metabolic Disorders in HepG2 Cells.
    Zeng L, Tang W, Yin J, Feng L, Li Y, Yao X, Zhou B.
    Cell Physiol Biochem; 2016 May 24; 40(3-4):453-464. PubMed ID: 27889747
    [Abstract] [Full Text] [Related]

  • 8. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
    Liou CJ, Wei CH, Chen YL, Cheng CY, Wang CL, Huang WC.
    Cell Physiol Biochem; 2018 May 24; 49(5):1870-1884. PubMed ID: 30235452
    [Abstract] [Full Text] [Related]

  • 9. Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD.
    Weber M, Mera P, Casas J, Salvador J, Rodríguez A, Alonso S, Sebastián D, Soler-Vázquez MC, Montironi C, Recalde S, Fucho R, Calderón-Domínguez M, Mir JF, Bartrons R, Escola-Gil JC, Sánchez-Infantes D, Zorzano A, Llorente-Cortes V, Casals N, Valentí V, Frühbeck G, Herrero L, Serra D.
    FASEB J; 2020 Sep 24; 34(9):11816-11837. PubMed ID: 32666604
    [Abstract] [Full Text] [Related]

  • 10. Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index.
    Aoki C, Suzuki K, Kuroda H, Sagara M, Shimizu M, Kasai K, Aso Y.
    Nagoya J Med Sci; 2017 Feb 24; 79(1):9-16. PubMed ID: 28303056
    [Abstract] [Full Text] [Related]

  • 11. Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice.
    Kawashima S, Matsuoka TA, Kaneto H, Tochino Y, Kato K, Yamamoto K, Yamamoto T, Matsuhisa M, Shimomura I.
    Biochem Biophys Res Commun; 2011 Jan 07; 404(1):534-40. PubMed ID: 21144823
    [Abstract] [Full Text] [Related]

  • 12. Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis.
    Amano Y, Tsuchiya S, Imai M, Tohyama K, Matsukawa J, Isono O, Yasuno H, Enya K, Koumura E, Nagabukuro H.
    Biochem Biophys Res Commun; 2018 Feb 26; 497(1):207-213. PubMed ID: 29428719
    [Abstract] [Full Text] [Related]

  • 13. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice.
    Hong Y, Choi SI, Hong E, Kim GH.
    J Food Sci; 2020 Jul 26; 85(7):2216-2226. PubMed ID: 32579753
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Activation of AMPK by triptolide alleviates nonalcoholic fatty liver disease by improving hepatic lipid metabolism, inflammation and fibrosis.
    Huang R, Guo F, Li Y, Liang Y, Li G, Fu P, Ma L.
    Phytomedicine; 2021 Nov 26; 92():153739. PubMed ID: 34592488
    [Abstract] [Full Text] [Related]

  • 16. Aliskiren Reduces Hepatic steatosis and Epididymal Fat Mass and Increases Skeletal Muscle Insulin Sensitivity in High-Fat Diet-Fed Mice.
    Lee KC, Hsieh YC, Yang YY, Chan CC, Huang YH, Lin HC.
    Sci Rep; 2016 Jan 06; 6():18899. PubMed ID: 26732252
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K, Ryu D, Dongiovanni P, Ozcan L, Nayak S, Ueberheide B, Valenti L, Auwerx J, Pajvani UB.
    Gastroenterology; 2017 Dec 06; 153(6):1568-1580.e10. PubMed ID: 28859855
    [Abstract] [Full Text] [Related]

  • 19. Hepatoprotective Effects of Soybean Embryo by Enhancing Adiponectin-Mediated AMP-Activated Protein Kinase α Pathway in High-Fat and High-Cholesterol Diet-Induced Nonalcoholic Fatty Liver Disease.
    Hong J, Kim S, Kim HS.
    J Med Food; 2016 Jun 06; 19(6):549-59. PubMed ID: 27266339
    [Abstract] [Full Text] [Related]

  • 20. Ameliorative effects and molecular mechanisms of vine tea on western diet-induced NAFLD.
    Xie K, He X, Chen K, Sakao K, Hou DX.
    Food Funct; 2020 Jul 01; 11(7):5976-5991. PubMed ID: 32666969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.